AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward

Med411.com Medical Award

HealthAtoZ.com Featured Site Award

BuscaSalud.com

IBS Tales Hope Award

HealingWell.com Editor's Choice Award

Listed in Listed in Treasures of the Internet


AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Reviewed September 23, 2013

Fact Sheet 472

Atripla (efavirenz + emtricitabine + tenofovir)


WHAT IS ATRIPLA?
WHO SHOULD TAKE ATRIPLA?
WHAT ABOUT DRUG RESISTANCE?
HOW IS ATRIPLA TAKEN?
WHAT ARE THE SIDE EFFECTS?
HOW DOES ATRIPLA REACT WITH OTHER DRUGS?
 


WHAT IS ATRIPLA?

Atripla is a tablet that contains three antiretroviral drugs (ARVs) used to fight HIV: efavirenz (Sustiva), emtricitabine (Emtriva), and tenofovir (Viread). Atripla is manufactured by Gilead and Bristol-Myers Squibb. It is the first tablet that includes a complete antiretroviral regimen. A generic version was approved for sale outside the US under the PEPFAR program (see fact sheet 925).

The drugs in Atripla are a non-nucleoside reverse transcriptase inhibitor (efavirenz) and two nucleoside analog reverse transcriptase inhibitors, or nukes (emtricitabine and tenofovir). These drugs block the reverse transcriptase enzyme. This enzyme changes HIV’s genetic material (RNA) into the form of DNA. This has to occur before HIV’s genetic code gets inserted into an infected cell’s own genetic codes.

 


WHO SHOULD TAKE ATRIPLA?

Atripla was approved in 2006 as an ARV for adults with HIV infection. Atripla should not be used in people younger than age 18. It has not been carefully studied in older adults. People with liver or kidney problems may not be able to take Atripla.

There are no absolute rules about when to start antiretroviral therapy (ART). You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking ART. Fact Sheet 404 more information about guidelines for the use of ART.

If you take Atripla, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.

Atripla provides three drugs in one pill. It can be more convenient to use Atripla than some other combinations of drugs. This could mean fewer missed doses and better control of HIV. Atripla can be an effective combination of ARVs in one pill.

 


WHAT ABOUT DRUG RESISTANCE?

Many new copies of HIV are mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance.”

 Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.

 

 


HOW IS ATRIPLA TAKEN?

Atripla is taken by mouth as a tablet. The normal adult dose is one tablet, once a day. Each tablet includes 600 milligrams (mg) of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir.

Atripla should be taken on an empty stomach. Taking Atripla at bedtime may help reduce side effects.  If you miss your dose, you can take Atripla up to 12 hours late.  Otherwise, take your next dose at the regular time.

Food with high fat content can increase levels of efavirenz and should not be eaten before taking a dose of Atripla.

 


WHAT ARE THE SIDE EFFECTS?

When you start any ART, you may have temporary side effects such as headaches, high blood pressure, or a general sense of feeling ill. These side effects usually get better or disappear over time.

The most common side effects of Atripla are the same as with the drugs it contains: efavirenz (see fact sheet 432), emtricitabine (see fact sheet 420), and tenofovir (see fact sheet 419). They include headache, diarrhea, nausea, vomiting, vivid dreams, anxiety, rash, dizziness, insomnia, and loss of appetite.

About 5% of patients taking efavirenz had serious psychiatric symptoms. If you are taking Atripla and experience serious depression or other psychiatric symptoms, talk to your health care provider right away.

If you have had hepatitis B or C, your liver function tests may increase significantly. These should be monitored carefully.

Studies in monkeys showed that efavirenz is likely to cause birth defects. Pregnant women should not take Atripla, especially during the first 3 months of pregnancy.

People who take Atripla may falsely test positive for marijuana use. To prove that the results are false, you would have to identify the drug that you are taking. This would mean disclosing that you have HIV infection.

 


 HOW DOES ATRIPLA REACT WITH OTHER DRUGS?

Atripla can interact with other drugs or supplements you are taking. These interactions can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are constantly being identified. Make sure that your health care provider knows about ALL drugs and supplements you are taking.

Drugs to watch out for include other ARVs, drugs to treat tuberculosis (see fact sheet 518), for erectile dysfunction (such as Viagra), for heart rhythm (antiarrhythmics), and for migraine headaches. Interactions are also possible with several antihistamines (allergy medications), sedatives, drugs to lower cholesterol, and anti-fungal drugs.

Efavirenz decreases blood levels of methadone. Efavirenz can lower concentrations of buprenorphine. Be aware of these interactions if you take Atripla.

The herb St. John's Wort (See Fact Sheet 729) lowers the blood levels of some non-nucleoside reverse transcriptase inhibitors. Do not take it with Atripla.

 


 

 


Back to Fact Sheet Categories



New Mexico AIDS Education and Training Center The University of New Mexico Health Sciences Center International Association of Providers of AIDS Care

 

The AIDS InfoNet is a project of the New Mexico AIDS Education and Training Center at the University of New Mexico Health Sciences Center,
and the International Association of Providers of AIDS Care.
webmaster@aidsinfonet.org

 

United States National Library of Medicine

Partially funded by the National Library of Medicine



Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please provide your e-mail address below, and click on the "Submit" button.



Subscribe
Unsubscribe